Dashenlin Pharm Grp Co Ltd (603233.SS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE100002RG2
Dashenlin Pharm Grp Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 26.50 bn CNY | 27.50 bn CNY |
| Gross profit | 9.07 bn CNY | 9.44 bn CNY |
| Operating income | 1.35 bn CNY | 2.10 bn CNY |
| EBIT | 1.55 bn CNY | 1.93 bn CNY |
| Net income | 914.75 m CNY | 1.24 bn CNY |
| Diluted EPS – continuing operations | 0.81 CNY | 1.08 CNY |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Dashenlin Pharm Grp Co Ltd
DaShenLin Pharmaceutical Group Co., Ltd. engages in the manufacture, distribution, and retail of pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and tonic herbs, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.
More stocks
- Bethel Automotive Safety Systems Co Ltd Class A (603596.SS)
- Jiangsu Phoenix Publishing & Media Corp Ltd (601928.SS)
- AP Memory Technology Corp (6531.TW)
- Guangzhou Development Group Inc (600098.SS)
- Securetech Innovations, Inc. (SCTH)
- Anxin Trust Co Ltd (600816.SS)
- Xiamen Faratronic Co Ltd (600563.SS)
- Colonial SFL SOCIMI SA (COL.MC)
- Rigetti Computing, Inc. (RGTI)
- Nikon Corp (7731.T)
- Polaris Inc. (PII)
- Cirsa Enterprises SAU (CIRSA.MC)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.